Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Debt-to-Equity : 0.16 (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is Skystar Bio-Pharmaceutical Co Debt-to-Equity?

Skystar Bio-Pharmaceutical Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $19.18 Mil. Skystar Bio-Pharmaceutical Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2014 was $0.00 Mil. Skystar Bio-Pharmaceutical Co's Total Stockholders Equity for the quarter that ended in Sep. 2014 was $122.51 Mil. Skystar Bio-Pharmaceutical Co's debt to equity for the quarter that ended in Sep. 2014 was 0.16.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Skystar Bio-Pharmaceutical Co's Debt-to-Equity or its related term are showing as below:

SKBI's Debt-to-Equity is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 0.3
* Ranked among companies with meaningful Debt-to-Equity only.

Skystar Bio-Pharmaceutical Co Debt-to-Equity Historical Data

The historical data trend for Skystar Bio-Pharmaceutical Co's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Skystar Bio-Pharmaceutical Co Debt-to-Equity Chart

Skystar Bio-Pharmaceutical Co Annual Data

Trend

Dec04

Dec05

Dec06

Dec07

Dec08

Dec09

Dec10

Dec11

Dec12

Dec13

Debt-to-Equity

Get a 7-Day Free Trial

0.04

0.08

0.06

0.10

Skystar Bio-Pharmaceutical Co Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
Debt-to-Equity	Get a 7-Day Free Trial															0.10	0.10	0.05	0.17	0.16

Competitive Comparison of Skystar Bio-Pharmaceutical Co's Debt-to-Equity

For the Drug Manufacturers - General subindustry, Skystar Bio-Pharmaceutical Co's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Skystar Bio-Pharmaceutical Co's Debt-to-Equity Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Skystar Bio-Pharmaceutical Co's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Skystar Bio-Pharmaceutical Co's Debt-to-Equity falls into.

Skystar Bio-Pharmaceutical Co Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Skystar Bio-Pharmaceutical Co's Debt to Equity Ratio for the fiscal year that ended in Dec. 2013 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(10.641	+	0)	/	110.393
	=	0.10

Skystar Bio-Pharmaceutical Co's Debt to Equity Ratio for the quarter that ended in Sep. 2014 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(19.175	+	0)	/	122.505
	=	0.16

Skystar Bio-Pharmaceutical Co (GREY:SKBI) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Skystar Bio-Pharmaceutical Co Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Skystar Bio-Pharmaceutical Co's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Skystar Bio-Pharmaceutical Co (GREY:SKBI) » Definitions » Debt-to-Equity

Traded in Other Exchanges

N/A

Address

No. 48 Keji Road, 4/F Building B, Chuangye Square, Gaoxin District, Xian, Shaanxi Province, CHN

Website

http://www.skystarbio-pharmaceutical.com

Skystar Bio-Pharmaceutical Co is a holding company. Through its subsidiaries, it is engaged in the research, development, production, marketing, and sales of veterinary healthcare and medical care products in the People's Republic of China. The company provides individually packaged animal wellness and pharmaceutical products for retail sale. It generates revenue from the sales of four product lines namely, veterinary medications, micro-organism, feed additives, and vaccines. The firm develops, manufactures, packages and distributes vaccines; Western medicines, Traditional Chinese Medicine; topicals, supplements, probiotics; diagnostic kits and animal nutrition supplements for poultry, livestock, marine aquaculture and domesticated pets.

Skystar Bio-Pharmaceutical Co (Skystar Bio-Pharmaceutical Co) Headlines

No Headlines